Niagen Bioscience Hosts Virtual Q&A on Pharma Program
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 19 hours ago
0mins
Source: Newsfilter
- Leadership Showcase: CEO Rob Fried will discuss Niagen Bioscience's leadership in NAD+ science during a virtual Q&A on July 15, 2026, emphasizing innovations in healthy aging, which is expected to boost investor confidence in the company's future growth.
- Pharmaceutical Development Update: The session will introduce the company's newly launched pharmaceutical program targeting rare genetic diseases and aging-related disorders, indicating Niagen Bioscience's expansion into the biopharmaceutical sector, potentially opening new revenue streams and market opportunities.
- Interactive Engagement Opportunity: The Q&A segment will allow participants to directly ask Rob Fried questions, enhancing interaction between investors and management, which may improve investor perceptions of transparency and trust, positively impacting stock prices.
- Market Positioning Strengthening: As the global authority in NAD+ science, Niagen Bioscience aims to promote healthy aging through its patented product Niagen®, which is expected to further solidify its competitive advantage in the market, attracting more consumers interested in health supplements.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NAGE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NAGE
Wall Street analysts forecast NAGE stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 3.370
Low
12.00
Averages
16.33
High
23.00
Current: 3.370
Low
12.00
Averages
16.33
High
23.00
About NAGE
Niagen Bioscience, Inc. is a global bioscience company dedicated to promoting healthy aging. Its segments include Consumer Products, Ingredients segment, Analytical Reference Standards and Services and Pharmaceuticals. The Consumer Products segment provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors. The ingredients segment develops and commercializes proprietary-based ingredient technologies, including food-grade Niagen and pharmaceutical-grade Niagen, and supplies these ingredients as raw materials to the manufacturers of consumer products and outsourcing facilities. The Analytical Reference Standards and Services segment offer the supply of phytochemical reference standards and other research and development services. The Pharmaceutical segment focuses on the pharmaceutical development of its nicotinamide adenine dinucleotide (NAD) precursor portfolio for potential therapeutic applications in rare diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Niagen Bioscience Hosts Virtual Q&A on Pharma Program
- Leadership Showcase: CEO Rob Fried will discuss Niagen Bioscience's leadership in NAD+ science during a virtual Q&A on July 15, 2026, emphasizing innovations in healthy aging, which is expected to boost investor confidence in the company's future growth.
- Pharmaceutical Development Update: The session will introduce the company's newly launched pharmaceutical program targeting rare genetic diseases and aging-related disorders, indicating Niagen Bioscience's expansion into the biopharmaceutical sector, potentially opening new revenue streams and market opportunities.
- Interactive Engagement Opportunity: The Q&A segment will allow participants to directly ask Rob Fried questions, enhancing interaction between investors and management, which may improve investor perceptions of transparency and trust, positively impacting stock prices.
- Market Positioning Strengthening: As the global authority in NAD+ science, Niagen Bioscience aims to promote healthy aging through its patented product Niagen®, which is expected to further solidify its competitive advantage in the market, attracting more consumers interested in health supplements.
See More
Niagen Launches First Drug Candidate NB4168 for Rare Genetic Diseases
- Drug Development Milestone: Niagen Bioscience has officially launched its first drug candidate, NB4168, aimed at treating rare genetic diseases, marking a strategic expansion of the company's NAD+ platform into drug development, which is expected to significantly enhance its competitiveness in the biopharmaceutical sector.
- Clinical Research Backing: The development of NB4168 is supported by two independent clinical studies demonstrating significant efficacy of NR in Ataxia Telangiectasia (A-T), which reduces the risk associated with the development pathway and may provide new treatment options for patients.
- Market Demand: A-T affects approximately 1 in 40,000 individuals, and with no FDA-approved therapies currently available, the introduction of NB4168 not only fills a market gap but also has the potential to improve patients' quality of life, representing significant social value.
- Patent Protection Advantage: As a unique molecule, NB4168 is backed by strong patent protection, ensuring its exclusive market position and further solidifying Niagen Bioscience's leadership in NAD+ research.
See More
Niagen Bioscience to Present at East Coast IDEAS Investor Conference
- Conference Schedule: Niagen Bioscience will present at the East Coast IDEAS Investor Conference on June 11, 2026, at The Westin Times Square in New York, with CEO Rob Fried scheduled to deliver a live presentation from 2:40 to 3:15 PM, aimed at attracting investor interest in its healthy aging science.
- Executive Participation: CFO Ozan Pamir will also attend the conference to host one-on-one meetings with institutional investors, which not only strengthens the company's relationships with investors but also paves the way for future financing opportunities.
- Investor Engagement: Attendees can schedule one-on-one meetings with the management team by contacting their respective conference representatives or emailing Niagen@KCSA.com, facilitating enhanced trust and interest from investors in the company.
- Product Promotion: Niagen Bioscience focuses on its patented NAD+ booster Niagen® to advance healthy aging through scientific research, and this conference is expected to further elevate its visibility and influence in the market.
See More
Niagen Bioscience Renames Research Program to Strengthen NAD+ Leadership
- Research Collaboration Expansion: The Niagen Research Program has supported over 300 research collaborations with leading global institutions, contributing to the publication of 45 clinical studies on Niagen®, showcasing the company's leadership in NAD+ biology.
- Clinical Research Outcomes: Over 90% of the clinical studies conducted through the program are independent, exploring NAD+ roles across various systems including skeletal and brain tissues, thereby reinforcing Niagen's significance in healthy aging research.
- New Grant Program Initiated: The company has launched the Niagen Bioscience Trainee Grant Program, offering three $10,000 grants to graduate students and postdoctoral trainees, reflecting a commitment to supporting the next generation of NAD+ scientists.
- Updated Research Focus: The updated application and review process will support studies involving both oral and pharmaceutical-grade Niagen materials, with current priority areas including dermatologic science, cognitive function, and exercise performance, further advancing NAD+ application research.
See More
Niagen Bioscience Announces Upcoming Conference Participation
- Conference Schedule: Niagen Bioscience will participate in the 31st Annual Sohn Investment Conference on May 12, 2026, where CFO Ozan Pamir will showcase the company's focus on the science of healthy aging in the Emerging Company Pavilion.
- One-on-One Meetings: At the 4th Annual Benchmark Consumer One-On-One Conference on May 19, 2026, CEO Rob Fried and CFO Ozan Pamir will engage in one-on-one discussions with investors, enhancing connections with potential stakeholders.
- NAD+ Scientific Leadership: As a global authority on NAD+ science, Niagen Bioscience is dedicated to advancing healthspan through precision science and innovative solutions, highlighting its leadership in aging research.
- Product Advantages: Niagen® is the most effective NAD+ booster on the market, supporting Tru Niagen® as the number one NAD+ boosting oral supplement in the U.S., further solidifying the company's competitive edge in the health supplement market.
See More
Niagen Bioscience Reports Strong Q1 2026 Earnings with Growth Challenges
- Revenue Growth: Niagen Bioscience reported $31.5 million in revenue for Q1 2026, exceeding analyst expectations of $31.0256 million, with a net income of $6.3 million, reflecting a 14% year-over-year growth in its e-commerce segment, although reduced orders from some customers impacted overall growth.
- New Product Launches: The company introduced the Niagen+ at-home injection kit and the Niagen Nanocloud skincare product, with the former receiving strong market response and the latter nearly sold out during its pilot phase, set for a wide launch in October, which will enhance the product portfolio and drive future sales.
- Expense Adjustments: Management anticipates an increase in selling and marketing expenses in absolute dollars and as a percentage of net sales, reflecting the company's focus on marketing to address competitive pressures and enhance brand visibility.
- Cash Flow Dynamics: Despite a net cash usage of $1.2 million in operations during Q1, primarily due to inventory investments and the impact of Amazon's sales policy, management remains optimistic about achieving a 10%-15% revenue growth outlook for the year, demonstrating resilience in the face of challenges.
See More
Niagen Bioscience Hosts Virtual Q&A on Pharma Program
- Leadership Showcase: CEO Rob Fried will discuss Niagen Bioscience's leadership in NAD+ science during a virtual Q&A on July 15, 2026, emphasizing innovations in healthy aging, which is expected to boost investor confidence in the company's future growth.
- Pharmaceutical Development Update: The session will introduce the company's newly launched pharmaceutical program targeting rare genetic diseases and aging-related disorders, indicating Niagen Bioscience's expansion into the biopharmaceutical sector, potentially opening new revenue streams and market opportunities.
- Interactive Engagement Opportunity: The Q&A segment will allow participants to directly ask Rob Fried questions, enhancing interaction between investors and management, which may improve investor perceptions of transparency and trust, positively impacting stock prices.
- Market Positioning Strengthening: As the global authority in NAD+ science, Niagen Bioscience aims to promote healthy aging through its patented product Niagen®, which is expected to further solidify its competitive advantage in the market, attracting more consumers interested in health supplements.
See More
Niagen Launches First Drug Candidate NB4168 for Rare Genetic Diseases
- Drug Development Milestone: Niagen Bioscience has officially launched its first drug candidate, NB4168, aimed at treating rare genetic diseases, marking a strategic expansion of the company's NAD+ platform into drug development, which is expected to significantly enhance its competitiveness in the biopharmaceutical sector.
- Clinical Research Backing: The development of NB4168 is supported by two independent clinical studies demonstrating significant efficacy of NR in Ataxia Telangiectasia (A-T), which reduces the risk associated with the development pathway and may provide new treatment options for patients.
- Market Demand: A-T affects approximately 1 in 40,000 individuals, and with no FDA-approved therapies currently available, the introduction of NB4168 not only fills a market gap but also has the potential to improve patients' quality of life, representing significant social value.
- Patent Protection Advantage: As a unique molecule, NB4168 is backed by strong patent protection, ensuring its exclusive market position and further solidifying Niagen Bioscience's leadership in NAD+ research.
See More
Niagen Bioscience to Present at East Coast IDEAS Investor Conference
- Conference Schedule: Niagen Bioscience will present at the East Coast IDEAS Investor Conference on June 11, 2026, at The Westin Times Square in New York, with CEO Rob Fried scheduled to deliver a live presentation from 2:40 to 3:15 PM, aimed at attracting investor interest in its healthy aging science.
- Executive Participation: CFO Ozan Pamir will also attend the conference to host one-on-one meetings with institutional investors, which not only strengthens the company's relationships with investors but also paves the way for future financing opportunities.
- Investor Engagement: Attendees can schedule one-on-one meetings with the management team by contacting their respective conference representatives or emailing Niagen@KCSA.com, facilitating enhanced trust and interest from investors in the company.
- Product Promotion: Niagen Bioscience focuses on its patented NAD+ booster Niagen® to advance healthy aging through scientific research, and this conference is expected to further elevate its visibility and influence in the market.
See More
Niagen Bioscience Renames Research Program to Strengthen NAD+ Leadership
- Research Collaboration Expansion: The Niagen Research Program has supported over 300 research collaborations with leading global institutions, contributing to the publication of 45 clinical studies on Niagen®, showcasing the company's leadership in NAD+ biology.
- Clinical Research Outcomes: Over 90% of the clinical studies conducted through the program are independent, exploring NAD+ roles across various systems including skeletal and brain tissues, thereby reinforcing Niagen's significance in healthy aging research.
- New Grant Program Initiated: The company has launched the Niagen Bioscience Trainee Grant Program, offering three $10,000 grants to graduate students and postdoctoral trainees, reflecting a commitment to supporting the next generation of NAD+ scientists.
- Updated Research Focus: The updated application and review process will support studies involving both oral and pharmaceutical-grade Niagen materials, with current priority areas including dermatologic science, cognitive function, and exercise performance, further advancing NAD+ application research.
See More
Niagen Bioscience Announces Upcoming Conference Participation
- Conference Schedule: Niagen Bioscience will participate in the 31st Annual Sohn Investment Conference on May 12, 2026, where CFO Ozan Pamir will showcase the company's focus on the science of healthy aging in the Emerging Company Pavilion.
- One-on-One Meetings: At the 4th Annual Benchmark Consumer One-On-One Conference on May 19, 2026, CEO Rob Fried and CFO Ozan Pamir will engage in one-on-one discussions with investors, enhancing connections with potential stakeholders.
- NAD+ Scientific Leadership: As a global authority on NAD+ science, Niagen Bioscience is dedicated to advancing healthspan through precision science and innovative solutions, highlighting its leadership in aging research.
- Product Advantages: Niagen® is the most effective NAD+ booster on the market, supporting Tru Niagen® as the number one NAD+ boosting oral supplement in the U.S., further solidifying the company's competitive edge in the health supplement market.
See More
Niagen Bioscience Reports Strong Q1 2026 Earnings with Growth Challenges
- Revenue Growth: Niagen Bioscience reported $31.5 million in revenue for Q1 2026, exceeding analyst expectations of $31.0256 million, with a net income of $6.3 million, reflecting a 14% year-over-year growth in its e-commerce segment, although reduced orders from some customers impacted overall growth.
- New Product Launches: The company introduced the Niagen+ at-home injection kit and the Niagen Nanocloud skincare product, with the former receiving strong market response and the latter nearly sold out during its pilot phase, set for a wide launch in October, which will enhance the product portfolio and drive future sales.
- Expense Adjustments: Management anticipates an increase in selling and marketing expenses in absolute dollars and as a percentage of net sales, reflecting the company's focus on marketing to address competitive pressures and enhance brand visibility.
- Cash Flow Dynamics: Despite a net cash usage of $1.2 million in operations during Q1, primarily due to inventory investments and the impact of Amazon's sales policy, management remains optimistic about achieving a 10%-15% revenue growth outlook for the year, demonstrating resilience in the face of challenges.
See More
